LEP and metabolic dysfunction-associated steatohepatitis: For instance, instead of descriptive results, interventional and controlled studies using leptin or leptin antagonists may help to clarify its role in NAFLD and to evaluate its potential use as a treatment or biomarker of the disease, either at initial steps or at more advanced levels such as NASH with or without fibrosis.